Cullinan Oncology

Nuvation Bio

Longboard Pharmaceuticals

Syndax Pharmaceuticals

Kura Oncology, Inc.

Incyte Corporation

HOOKIPA Pharma

Celcuity Inc

HUTCHMED China

REC-994 — spinocerebellar ataxia type 3

Dilution score: 21/100 (LOW), 24.0 months cash

Short interest: 19.61% of float, squeeze risk: MODERATE

239 PubMed publications found for Cullinan Oncology

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.

Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results.

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial.

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.

Short interest: 19.87% of float, squeeze risk: MODERATE

Dilution score: 15/100 (LOW), 41.1 months cash

237 PubMed publications found for Cullinan Oncology

When herds overgraze: the cost of conformity in oncology drug development.

Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial.

SW convergence: 50/100 (Neutral), 1 bullish / 0 bearish signals

Short interest: 19.88% of float, squeeze risk: MODERATE

236 PubMed publications found for Cullinan Oncology

Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.

Short interest: 18.33% of float, squeeze risk: MODERATE

SW convergence: 50/100 (Neutral), 2 bullish / 1 bearish signals

Dilution score: 14/100 (LOW), 41.8 months cash

Short interest: 18.73% of float, squeeze risk: MODERATE

Dilution score: 14/100 (LOW), 45.2 months cash

235 PubMed publications found for Cullinan Oncology

Short interest: 18.78% of float, squeeze risk: MODERATE

<article class="bts-verified-summary" data-ticker="CGEM">
<p>Cullinan Oncology (CGEM) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>No Form 4 insider filings for CGEM were recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR · 0001789972 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22CGEM%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR — 0001789972

Cullinan Oncology (CGEM) — BioTechSigns Verified Summary

Cullinan Oncology (CGEM) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

No Form 4 insider filings for CGEM were recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR, 0001789972. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22CGEM%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11